Human respiratory syncytial virus (RSV) is a common respiratory virus which is now recognized as an important pathogen in adults,
especially the elderly. In adults, about 1.5m episodes of RSV-ARI occur in industrialized countries. Globally, 336,000 hospital admissions and 14,000 in-hospital deaths have been estimated although
the true burden is believed to be higher (Shi T et al., 2020). In the USA 60-160,000 hospitalizations are estimated for persons >65 yrs with around 6-10,000 deaths (CDC, RSV-NET cited figures),
again with wide variance in estimates. Cardiovascular, chronic lung and diabetes are common underlying conditions in persons (>18 yrs) hospitalized with RSV infection with in-hospital mortality at ~12% (Shi T et al., 2022).
There is no specific treatment for RSV infection and for those adults who require hospitalization, supportive therapy is still the mainstay of care.
The RSV older adult, elderly vaccine development field is one of the most active in the industry with several pivotal Phase 3 studies now ongoing, 3 of which have met pre-specified primary endpoints in 2023.
Major companies such as Pfizer, PF-06928316 (ABRYSVO), GSK Biologicals, GSK3844766A (AREXVY), Janssen NV, Ad26.RSV.preF (VAC18193), ModernaTX, mRNA-1345, Sanofi Pasteur, CL-0059, CL-0137 and Bavarian Nordic, MVA-BN-RSV
have a range of vaccine approaches including mRNA technologies which could facilitate future combination pan-respiratory vaccines, already emerging in seasonal influenza and COVID-19 (mRNA-1073, 1230, 1045).
The US ACIP committee met in October 2022 to discuss the Pfizer and GSK datasets and is expected to make a policy decision in June 2023, post FDA PDUFA dates in May 2023 for those manufacturers who have already filed regulatory submissions. New February Q1 ACIP and FDA VRBPAC meetings have recently voted in favour of both vaccines and discussed further efficacy and safety matters.
This MarketVIEW product is a comprehensive Executive Presentation (~300 slides, .pdf) and interactive MS-Excel forecast model(s) which investigate the scenario-based
commercial potential of RSV older adult elderly vaccines profiles to 2037. 52 countries are included (public/private sector) where the impact of different
country specific pricing analogues, at risk stratifications and cohort target ranges can be explored. The new 2023 model can accommodate both yearly and 2-yearly schedules and the potential impact of combination products.
This report contains a thorough review of disease background/epidemiology/cost-effectiveness studies along with vaccinology/R&D competitive landscape with an emphasis on future product differentiators, product longevity & company specific revenues/share per
USA, EU, Developed ROW and Emerging markets. It is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV older adult, elderly vaccines future market.
THIS PRODUCT IS A SUMMARY PRESENTATION (~300 slides, .pdf) + scenario-based interactive MS Excel Workbook(s)
Photo credit: iStock (Getty Images)
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.